{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T14:30:35Z","timestamp":1774621835131,"version":"3.50.1"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001411","name":"Indian Council of Medical Research","doi-asserted-by":"publisher","award":["IIRPSG-2024-01-01573"],"award-info":[{"award-number":["IIRPSG-2024-01-01573"]}],"id":[{"id":"10.13039\/501100001411","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001409","name":"Department of Science and Technology, Ministry of Science and Technology, India","doi-asserted-by":"publisher","award":["SR\/PURSE\/2023\/220"],"award-info":[{"award-number":["SR\/PURSE\/2023\/220"]}],"id":[{"id":"10.13039\/501100001409","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016045","name":"University of Central Punjab","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016045","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100029379","name":"Arthur N. Rupe Foundation","doi-asserted-by":"publisher","award":["CRG\/2023\/001580"],"award-info":[{"award-number":["CRG\/2023\/001580"]}],"id":[{"id":"10.13039\/100029379","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry Letters"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.bmcl.2025.130431","type":"journal-article","created":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T06:49:26Z","timestamp":1759992566000},"page":"130431","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Targeted design, synthesis, molecular simulation, ADME-T and in-vitro anticancer assessment of phenyl-substituted-thioxo-tetrahydro-pyrimidin-benzenesulfonamide derivatives as potential BRAFV600E\/WT inhibitors"],"prefix":"10.1016","volume":"130","author":[{"given":"Ankit Kumar","family":"Singh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vineet","family":"Prajapati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adarsh","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vimlendu Kumar","family":"Sah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prateek","family":"Pathak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mashooq A.","family":"Bhat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed A.","family":"Al-Omar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amita","family":"Verma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pradeep","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.bmcl.2025.130431_bb0005","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.cell.2018.03.035","article-title":"Oncogenic signaling pathways in the cancer genome atlas","volume":"173","author":"Sanchez-Vega","year":"2018","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.bmcl.2025.130431_bb0010","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s13293-020-00291-x","volume":"11","author":"Rubin","year":"2020","journal-title":"Biol Sex Differ"},{"key":"10.1016\/j.bmcl.2025.130431_bb0015","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.gene.2019.02.076","article-title":"The relation between PI3K\/AKT signalling pathway and cancer","volume":"698","author":"Noorolyai","year":"2019","journal-title":"Gene"},{"key":"10.1016\/j.bmcl.2025.130431_bb0020","series-title":"Melanoma-From Early Detection to Treatment","first-page":"29","article-title":"Targeted therapies in melanoma: successes and pitfalls","author":"Palmieri","year":"2013"},{"key":"10.1016\/j.bmcl.2025.130431_bb0025","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.ejca.2016.12.010","article-title":"The mitogen-activated protein kinase pathway in melanoma part I\u2013activation and primary resistance mechanisms to BRAF inhibition","volume":"73","author":"Amaral","year":"2017","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.bmcl.2025.130431_bb0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/nrdp.2015.3","article-title":"Melanoma","volume":"1","author":"Schadendorf","year":"2015","journal-title":"Nat Rev Dis Primers"},{"issue":"22","key":"10.1016\/j.bmcl.2025.130431_bb0035","doi-asserted-by":"crossref","first-page":"3446","DOI":"10.1002\/cncr.28864","article-title":"The MAPK pathway across different malignancies: a new perspective","volume":"120","author":"Burotto","year":"2014","journal-title":"Cancer"},{"issue":"8","key":"10.1016\/j.bmcl.2025.130431_bb0040","doi-asserted-by":"crossref","first-page":"4069","DOI":"10.1021\/acs.jmedchem.9b02083","article-title":"Discovery of selective small molecule degraders of BRAF-V600E","volume":"63","author":"Han","year":"2020","journal-title":"J Med Chem"},{"issue":"3","key":"10.1016\/j.bmcl.2025.130431_bb0045","doi-asserted-by":"crossref","first-page":"184","DOI":"10.5603\/MRJ.a2019.0033","article-title":"Signaling pathways in melanoma biology and new targeted therapeutic approaches","volume":"4","author":"Kie\u0142bik","year":"2019","journal-title":"Med Res J"},{"issue":"11","key":"10.1016\/j.bmcl.2025.130431_bb0050","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.3390\/genes11111342","article-title":"Emerging BRAF mutations in cancer progression and their possible effects on transcriptional networks","volume":"11","author":"\u015amiech","year":"2020","journal-title":"Genes"},{"issue":"7","key":"10.1016\/j.bmcl.2025.130431_bb0055","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.18632\/oncotarget.1892","article-title":"Pathways and therapeutic targets in melanoma","volume":"5","author":"Shtivelman","year":"2014","journal-title":"Oncotarget"},{"key":"10.1016\/j.bmcl.2025.130431_bb0060","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1479-5876-10-85","article-title":"The role of BRAF V600 mutation in melanoma","volume":"10","author":"Ascierto","year":"2012","journal-title":"J Transl Med"},{"issue":"1","key":"10.1016\/j.bmcl.2025.130431_bb0065","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/modpathol.2017.104","article-title":"Molecular testing for BRAF mutations to inform melanoma treatment decisions: a move toward precision medicine","volume":"31","author":"Cheng","year":"2018","journal-title":"Mod Pathol"},{"issue":"2","key":"10.1016\/j.bmcl.2025.130431_bb0070","first-page":"128","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"4","author":"Mathieu","year":"2024","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"10.1016\/j.bmcl.2025.130431_bb0075","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.sjbs.2014.10.002","article-title":"BRAF gene: from human cancers to developmental syndromes","volume":"22","author":"Hussain","year":"2015","journal-title":"Saudi J Biol Sci"},{"issue":"31","key":"10.1016\/j.bmcl.2025.130431_bb0080","doi-asserted-by":"crossref","first-page":"27819","DOI":"10.1021\/acsomega.3c00332","article-title":"Challenges and opportunities in the crusade of BRAF inhibitors: from 2002 to 2022","volume":"8","author":"Singh","year":"2023","journal-title":"ACS Omega"},{"issue":"3","key":"10.1016\/j.bmcl.2025.130431_bb0085","doi-asserted-by":"crossref","first-page":"278","DOI":"10.2174\/1871520622666220624164152","article-title":"Current insights into the role of BRAF inhibitors in treatment of melanoma","volume":"23","author":"Singh","year":"2023","journal-title":"Anti-Cancer Agents Med Chem"},{"issue":"10","key":"10.1016\/j.bmcl.2025.130431_bb0090","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1016\/j.bmc.2019.03.062","article-title":"Anticancer profile of newly synthesized BRAF inhibitors possess 5-(pyrimidin-4-yl) imidazo [2,1-b] thiazole scaffold","volume":"27","author":"Abdel-Maksoud","year":"2019","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.bmcl.2025.130431_bb0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113277","article-title":"Design, synthesis, biological evaluation, and docking studies of novel (imidazol-5-yl) pyrimidine-based derivatives as dual BRAFV600E\/p38\u03b1 inhibitors","volume":"215","author":"Ali","year":"2021","journal-title":"Eur J Med Chem"},{"issue":"19","key":"10.1016\/j.bmcl.2025.130431_bb0100","doi-asserted-by":"crossref","first-page":"10491","DOI":"10.3390\/ijms221910491","article-title":"Design, synthesis and anticancer profile of new 4-(1H-benzo[d]imidazol-1-yl) pyrimidin-2-amine-linked sulfonamide derivatives with V600EBRAF inhibitory effect","volume":"22","author":"Abdel-Maksoud","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.bmcl.2025.130431_bb0105","doi-asserted-by":"crossref","first-page":"143620","DOI":"10.1016\/j.molstruc.2025.143620","article-title":"Thioxo-tetrahydro-pyrimidin-benzenesulfonamide hybrids as potential BRAFV600E inhibitors: experimental, computational and biological evaluations","volume":"1349","author":"Singh","year":"2025","journal-title":"J Mol Struct"},{"issue":"1","key":"10.1016\/j.bmcl.2025.130431_bb0110","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/s41698-022-00341-0","article-title":"BRAF V600E\u2013mutant cancers treated with vemurafenib alone or in combination with everolimus, sorafenib, or crizotinib or with paclitaxel and carboplatin (VEM-PLUS) study","volume":"7","author":"Nelson","year":"2023","journal-title":"NPJ Precis Oncol"},{"issue":"46","key":"10.1016\/j.bmcl.2025.130431_bb0115","doi-asserted-by":"crossref","first-page":"30181","DOI":"10.1039\/D2RA05751D","article-title":"Gaussian field-based 3D-QSAR and molecular simulation studies to design potent pyrimidine\u2013sulfonamide hybrids as selective BRAFV600E inhibitors","volume":"12","author":"Singh","year":"2022","journal-title":"RSC Adv"}],"container-title":["Bioorganic & Medicinal Chemistry Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X25003403?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X25003403?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T08:15:41Z","timestamp":1761639341000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960894X25003403"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":23,"alternative-id":["S0960894X25003403"],"URL":"https:\/\/doi.org\/10.1016\/j.bmcl.2025.130431","relation":{},"ISSN":["0960-894X"],"issn-type":[{"value":"0960-894X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeted design, synthesis, molecular simulation, ADME-T and in-vitro anticancer assessment of phenyl-substituted-thioxo-tetrahydro-pyrimidin-benzenesulfonamide derivatives as potential BRAFV600E\/WT inhibitors","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmcl.2025.130431","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"130431"}}